COSCIENS Biopharma Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-10.4M | $-15.3M | $-3.5M | $3.4M | $-8.4M | $-5.1M | $-6.0M | $4.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | $9.0K | $9.0K | $17.0K | $35.0K |
| Amortization | — | — | — | $212 | $16.0K | $20.0K | $20.0K | $23.0K |
| Stock-Based Compensation | $6.4M | $5.2M | $3.9M | $3.4M | $311.0K | $61.0K | — | $108.0K |
| Net Cash from Operating Activities | $-8.5M | $-14.6M | $-2.6M | $5.2M | $-8.6M | $-4.1M | $-10.7M | $6.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $706.0K | $1.2M | $722.0K | $304.0K | $30.0K | — | — | $9.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-458.0K | $25.1M | $-730.0K | $-304.0K | $-658.0K | $56.0K | $50.0K | $-35.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-407.0K | $-588.0K | $-357.0K | $-267.0K | $51.0M | $20.5M | $3.9M | $0 |
| Net Change in Cash | $-9.1M | $9.7M | $-3.5M | $4.0M | $41.0M | $16.4M | $-6.7M | $6.7M |
| Free Cash Flow | $-9.2M | $-15.7M | $-3.3M | $4.9M | $-8.6M | — | — | $6.8M |